1. The polymorphic inheritance of DIO2 rs225014 may predict body weight variation after Graves’ disease treatment
- Author
-
Natassia Elena Bufalo, Danilo Vilagellin, Laura Sterian Ward, Elisangela Souza Teixeira, João H. Romaldini, Ana Beatriz Pinotti Pedro Miklos, Ana Paula Comarella, Jessica Ferreira Euflauzino, and Roberto B. Santos
- Subjects
medicine.medical_specialty ,Multivariate analysis ,business.industry ,Endocrinology, Diabetes and Metabolism ,Graves' disease ,Graves’ Disease ,DIO2 ,medicine.disease ,Body weight ,RC648-665 ,DIO2 gene ,Gastroenterology ,Diseases of the endocrine glands. Clinical endocrinology ,SNP genotyping ,Weight loss ,Internal medicine ,Genotype ,medicine ,Medicine ,medicine.symptom ,business ,polymorphisms ,Genotyping - Abstract
Objective: We aimed to investigate the role of DIO2 polymorphisms rs225014 and rs12885300 in Graves’ disease patients, mainly for controlling body weight following treatment. Subjects and methods: We genotyped 280 GD patients by the time of diagnosis and 297 healthy control individuals using a TaqMan SNP Genotyping technique. We followed up 141 patients for 18.94 ± 6.59 months after treatment. Results: There was no relationship between the investigated polymorphisms with susceptibility to GD and gain or loss of weight after GD treatment. However, the polymorphic inheritance (CC+CT genotype) of DIO2 rs225014 was associated with a lower body weight variation after GD treatment (4.26 ± 6.25 kg) when compared to wild type TT genotype (6.34 ± 7.26 kg; p = 0.0456 adjusted for the follow-up time). This data was confirmed by a multivariate analysis (p = 0.0138) along with a longer follow-up period (p = 0.0228), older age (p = 0.0306), treatment with radioiodine (p-value = 0.0080) and polymorphic inheritance of DIO2 rs12885300 (p = 0.0306). Conclusion: We suggest that DIO2 rs225014 genotyping may have an auxiliary role in predicting the post-treatment weight behavior of GD patients.
- Published
- 2020